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Abstract
Aims: To determine prospectively the efficacy, tolerability and patient satisfaction of an extended release
formulation of metformin (metformin XR) in hospital based outpatients with type 2 diabetes mellitus currently
treated with standard metformin.
Methods: Patients on immediate release standard metformin either alone or combined with other oral agents
were switched to extended release metformin XR 500 mg tablets and titrated to a maximum dose of 2000 mg/day
Measurements to include glucose and lipid control, blood pressure, body weight, waist circumference, C-reactive
protein, adverse events and patient satisfaction were recorded at baseline, three and six months.
Results: Complete data were obtained for 35 of the 61 patients enrolled to the study. At three and six months no
changes were reported for any of the cardiovascular risk factors except for lipids where there was a modest rise in
plasma triglycerides. These effects were achieved with a reduced dose of metformin XR compared to pre-study
dosing with standard metformin (1500 mg +/- 402 vs 1861 +/- 711 p = 0.004). A total of 77% of patients were free
of gastrointestinal side effects and 83% of patients stated a preference for metformin XR at the end of the study.
Ghost tablets were reported in the faeces by the majority of the patients (54.1%).
Conclusions: Patients switched to extended release metformin XR derived the same clinical and metabolic
benefits as for standard metformin but with reduced dosage, fewer gastrointestinal side effects and a greater sense
of well being and satisfaction on medication.
Introduction
Type 2 Diabetes Mellitus is a chronic and progressive
disease which demands intense management from diag-
nosis and through the various stages of the disease [1,2].
Its epidemic proportions worldwide [3], including Brazil
[4], make it a public health issue and the present goal is
to implement policies aimed at both its prevention [5,6]
and management [7,8].
Lifestyle change and the use of pharmaceutical thera-
pies are considered pivotal to achieving good control of
glycaemia and other cardiovascular risk factors in the
expectation of avoiding long-term complications and
premature mortality [9]. Metformin is recommended in
International Guidelines [7,8] as first line therapy due to
its favourable profile on metabolic indices of glucose,
lipid and weight control [10] as well as offering protec-
tion from life threatening complications and premature
mortality [11,12].
Standard metformin suffers from the limitations of
having to be administered two or three times a day and
with the attendant risk of triggering gastrointestinal
symptoms affecting 25% of patients making dose optimi-
zation problematic [13,14]. The joint consensus state-
ment from the American Diabetes Association (ADA)
and the European Society for the study of Diabetes
(EASD) recognize these difficulties and give advice on
how to minimize poor compliance with standard met-
formin [8]. Compliance is an issue for all chronic dis-
eases [15] and poor tablet adherence is a particular
concern in managing patients with diabetes due to the
burden of medication [16,17]. In the 5 point plan for
introducing metformin, the ADA/EASD draw attention
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This prospective study sets out to determine the ability
of hospital based outpatients with type 2 diabetes to
switch from standard metformin to extended release for-
mulation (metformin XR). Moreover, to assess the resul-
tant benefits on cardiovascular risk factors including
glycaemia, plasma lipids, blood pressure, body weight
a n da n t h r o p o m e t r i cm e a s u r e m e n t sa sw e l la sm e a s u r e s
of tolerability and patient satisfaction.
Patients and Methods
Study design
This was an open-label, prospective 24-week study con-
ducted in patients with type 2 diabetes who were outpa-
tients of the diabetes clinic at the State University of Rio
de Janeiro. Approved by the local ethics committee,
patient enrollment was restricted to the following
patients: those aged 18 years and greater and taking
immediate release metformin alone or in combination
with other oral agents, had symptoms of poor diabetes
control, were pregnant, serum creatinine levels > 1.3
mg/dL (female) or 1.4 mg/dL (male), nephropathy, evi-
dence of hepatic disease or history of alcohol abuse.
Assessments were at baseline whilst on immediate
release metformin, then at 3 and 6 months respectively
following switchover to the once-a-day extended release
metformin (Diabex XR or Glucophage SR/XR in Eur-
ope). At baseline, patients were started on the 500 mg
XR tablet taken with the evening meal and titrated up
to a maximum of four tablets per day.
The effectiveness of the extended release tablet was
measured on three cardiovascular risk factors - blood
glucose [HbA1c, fasting blood glucose (FBG), and post-
prandial blood glucose (PPBG)] blood lipids [total cho-
lesterol, LDL cholesterol (Friedwald calculation) HDL
cholesterol and triglycerides] and blood pressure. Body
w e i g h tw a sm e a s u r e da sB M I ,a sw e r et h ea n t h r o p o -
metric measures of waist circumference and waist/hip
ratio (WHR). Other laboratory measurements included
serum high sensitive C-reactive protein (CRP) the albu-
min excretion rate (AER) and vitamin B12 levels.
Gastrointestinal tolerability and adverse events were
assessed at baseline and on completion of the study. All
reported events were classified as unrelated or related to
the study medication. Patient satisfaction forms were
completed by patients to gain a measure of acceptability
of the extended release tablet over standard metformin.
Methods
All patients passed urine immediately before 8 p.m., dis-
carded this sample and recorded the time. All the urine
passed until 6 a.m. was collected into containers without
a preservative. The urine volume was recorded, and ali-
quots were stored in glass tubes at - 70° Celsius until
analysis. Fasting blood samples were also obtained. The
urinary albumin concentration was estimated by solid-
phase competitive chemiluminescent enzyme immu-
noassay (Immulite 1000 Systems, DPC Medlab, Los
Angeles, CA, sensitivity of 0.5 ug/ml) with intra-assay
and inter-assay coefficients of variation of 4.4% and
6.1%, respectively. Based on the AER in at least two out
of three overnight urine specimens, patients were
divided into two groups: Microalbuminuria (AER ≥ 20
ug/min and < 200 ug/min in two out of three overnight
urine specimens) and normoalbuminuria (AER < 20 ug/
min in two out of three overnight urine specimens).
Each urine specimen was tested for bacteriuria, and




Blood pressure was measured by the same observer 3
times after a 5-min rest in the supine position using a
standard mercury sphygmomanometer. Diastolic blood
pressure (dBP) was recorded at the disappearance of
Korotkoff sounds (phase 5). The mean of the measure-
ments of systolic and diastolic blood pressure was used.
Hypertension was defined as systolic blood pressure
(sBP) > 140 mmHg and/or dBP > 90 mm Hg [2] or any
value in patients under antihypertensive treatment.
Blood samples were drawn in the morning between 7:30
and 8:30 a.m., after the last urine collection and an over-
night fast. After centrifugation at 2500 × g for 15 min at
room temperature (19°Celsius), aliquots of plasma and
sera were stored at -70° Celsius until analysis. Serum
CRP (mg/dl) was measured using a highly sensitive
immunonephelometry assay (Behring Nephelometer,
Germany) with a detection limit of 0.01 mg/dl and with
intra-assay and inter-assay CV of 1% and 5.3%, respec-
tively. Vitamin B12 was determined by an enzyme
immunoassay method (reference value: 180-914 pg/mL).
Creatinine (mg/dl), FBG (mg/dl), postprandial plasma
glucose (PPG, mg/dl), triglyceride (mg/dl), HDL choles-
terol (mg/dl) and total cholesterol (mg/dl) levels were
measured using an auto-analyzer (Cobas-Mira Roche)
by enzymatic techniques. Postprandial glucose was mea-
sured two hours after the usual breakfast. Patients were
instructed to take their usual medication.
Body mass index (BMI) was calculated by dividing the
weight (kg) by height squared (m
2). Anthropometric
measurements were taken in a standing position after
subjects removed their heavy clothes. WHR was mea-
sured twice, and the mean value was used for analysis.
Waist and hip circumferences were measured on bare
skin at the level of the umbilicus and iliac crest, respec-
tively, during mid-respiration to the nearest 0.5 cm. The
WHR was defined according to the average of two
duplicate measurements.
Charts were reviewed to verify other relevant medical
conditions, including micro and macrovascular
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A simple satisfaction questionnaire comprising four
questions (Do you fell better with metforminXR? Do
you think that diarrhea, nausea an vomiting are limiting
symptoms to use Metformin ? Do you think that com-
pliance is better using Metformin XR ? Do you want to
get back to Metformin?) was applied to the patients at
the end of the study.
Statistical Analysis
The Student t- test was used for comparisons of contin-
uous dependent (intra-group) and continuous indepen-
dent variables (inter-group). Chi-Square with Yates
correction and Fisher’s exact test were used for compar-
ison of categorical variables. These analyses were per-
formed using the statistical package for the social
sciences (SPSS, version 13.0). Values were expressed as
mean (± SD) or median (minimum/maximum). A two-
sided P value of less than 0.05 was considered to be
significant.
Results
A total of 177 patients were interviewed for possible
enrolment of which 61 patients met the entry criteria.
There was a preponderance of women (n = 40) and the
age was 54.1 ± 12.1 years with a duration of diabetes of
7.3 ± 6.5 years. Some 28 patients at baseline (45.9%) had
gastrointestinal symptoms with persistent use of stan-
dard metformin, and diarrhoea was described as the
major gastrointestinal side effect in 16 cases. Other
patients reported nausea (4 cases), diarrhoea and nausea
(4 cases) and epigastric and abdominal pain in a further
2 cases for each. In a quarter of patients the symptoms
had been severe enough in the past to precipitate tem-
porary discontinuation of metformin. The majority, 35
patients (54.1%), reported the presence of ghost tablets
of metformin XR in their feces during the use of the
medication. Microalbuminuria was found in 38 patients
(62.2%).
Over the 6 months of follow up, a total of 26 patients
withdrew from the study including 23 patients who
withdrew voluntarily, 2 patients who started on insulin,
and 1 patient who unilaterally decided to resume treat-
ment with standard metformin without seeking medical
advice. For the remaining group comprising 35 patients,
no significant differences were observed for any of the
anthropometric, clinical or laboratory measures with the
exception of plasma triglycerides, (140.2 +/- 74.8 vs
202.9 +/- 102.2 p = 0.01) following switchover to
extended release metformin at 3 and 6 months respec-
tively (Table 1). The metformin daily dose at baseline
and following titration of metformin XR was 1861 +/-
711 mg and 1500 +/- 402 mg per day (p = 0.004)
respectively. On completion of six months on
metformin XR, a total of 27 patients (77.1%) were
asymptomatic, with the remainder reporting symptoms
of diarrhoea (n = 5), nausea (n = 2) and epigastric pain
(n = 1) [Figure 1].
The results of the patient satisfaction questionnaire
indicated that 29 patients (82.9%) felt better on metfor-
min XR whilst one patient reported feeling worse and a
further 5 patients stated no treatment preference.
Discussion
Metformin is recommended as a core therapy in dia-
betes management worldwide at diagnosis and is seen as
being complementary to lifestyle change either alone or
in combination with other oral antidiabetic therapies or
insulin [8]. The ADA/EASD guidelines mention its use
in patients irrespective of age, body weight and degree
of baseline hyperglycaemia. Its not therefore surprising
that in populations as diverse as this that the use of
standard immediate release metformin is problematic in
some patient groups leading to difficulties with dose
optimization [18]. Limitations to its introduction include
multiple dosing and gastrointestinal upsets including
diarrhoea, nausea and abdominal pain. A majority of
patients treated with metformin are GI symptom free
but upwards of 25% of patients experience dose limiting
side effects though discontinuation can be in the order
of 5%[14]. Gastrointestinal upset can be of a temporary
nature but in some cases is low grade and persistent
[19]. In the present study, over 77% of patients were GI
symptom free on completion of 6 months continuous
therapy on extended release metformin. This is note-
worthy as almost half the patients at enrolment had per-
sistent GI side effects on standard metformin. Other
studies which have examined tolerability outcomes fol-
lowing switchover have reported similar results [20,21].
The extended release metformin tablet releases metfor-
min from the upper GI tract for a longer period of time
thereby delaying its entry into the systemic circulation
[22,23]. Metered release of metformin from the tablet
and administration with the evening meal when gastric
residence time is at its longest are thought to be factors
in explaining better tolerability.
Switchover to Metformin XR led to a greater sense of
well being and patient satisfaction. These findings have
the potential to lead to better adherence with therapy.
Donnelly and colleagues from Dundee have reported
greater adherence in patientss w i t c h e df r o ms t a n d a r d
metformin to an extended release [24]. Moreover, in the
same study glycaemic control was reported to improve
by almost 1% but small numbers prevented the change
becoming significant. According to projections from
UKPDS, a 1% decrement in HbA1c is associated with a
14% reduction in risk of heart attacks and a 37% reduc-
tion in risk of microvascular complications [25].
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min to the extended release metformin XR tablet is
associated with a neutral outcome on cardiovascular risk
factors. No detrimental changes were reported for mea-
sures of glycaemia, blood pressure. body weight or
anthopometric indices and this has been confirmed by
others [26].
T h es a m ew a st r u ef o rc h o l e s t e r o l ,L D Lc h o l e s t e r o l
and HDL cholesterol. A modest rise was reported for
plasma triglycerides and this has been reported before
[26,27]. This could reflect the time of administration of
metformin XR rather than the formulation. With an
evening administration, metformin plasma and tissue
concentrations are likely to be higher during the night-
time period whereas metformin dosing during the day
will lead to higher concentrations at the time of meals
and nutrient intake. Plasma triglycerides have been
shown to be related to plasma concentrations of metfor-
min [28].
Some concern was expressed by patients that the met-
formin XR tablet appears to be eliminated in the faeces
and is recognizable as a tablet shape. Patients need to
be forewarned that this is expected and is a function of
the tablet formulation [22]. The extended release prop-
erties of the tablet are due to the presence of two inso-
luble polymers one of which contains metformin. As the
Table 1 Clinical and laboratory data at baseline and 3 and 6 months of follow-up
Variables Baseline Follow up (90 days) Follow up (180 days) p value
80.78 ± 15.91 79.98 ± 14.98 80.52 ± 15.63 0.12
BMI (kg/m
2) 31.18 ± 5.42 30.85 ± 5.09 31.03 ± 5.17 0.82
WHR (cm) 101.77 ± 11.24 100.67 ± 10.21 100.53 ± 10.71 0.12
HbA1c (%) 7.61 ± 1.53 7.58 ± 1.44 7.68 ± 1.50 0.713
Cholesterol (mg/dl) 189.33 ± 40.78 191.17 ± 38.39 190.03 ± 42.12 0.945
Triglycerides (mg/dl) 142.53 ± 75.12 186.17 ± 162.79 185.28 ± 139.27 0.088
LDL Chol (mg/dl) 114.59 ± 32.93 109.50 ± 31.18 109.19 ± 33.78 0.463
HDL Chol (mg/dl) 48.51 ± 10.39 48.83 ± 9.07 46.89 ± 10.24 0.242
Vitamin B12 (pg/dl) 293.91 ± 126.54 287.46 ± 122.65 291.57 ± 132.26 0.844
CRP (mg/dl) 0.352 ± 0.31 0.431 ± 0.28 0.372 ± 0.35 0.327
AER (mg/min) 21.04 ± 53.24 27.44 ± 77.76 27.36 ± 75.76 0.309
Data are presented as means ± standard deviation.
Abbreviations: BMI: Body mass index; WHR: Waist/hip ratio;
HbA1C: glycated haemoglobin; CRP: C-reactive protein; AER: Albumin Excretion rate
Figure 1 Incidence of Gastrointestinal side effects before and afters w i t c h o v e rt oe x t e n d e dr e l e a s em e t f o r m i nX Ri np a t i e n t s
completing the 6 month study. * vs metformin p = 0.013.
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swells due to hydration of the outer polymer thereby
creating a gel covering. For absorption to take place,
metformin must penetrate the outer layer. The intact-
ness of the tablet shape underscores the performance of
the extended release tablet.
Switchover to metformin XR had no effect on hs C-
reactive protein, a biomarker of chronic inflammatory
disease. Previous studies have shown mixed results of
metformin therapy on C-reactive protein and overall,
studies in non-diabetics [29,30] rather than diabetics
[31] have reported greater inhibitory effects. As patients
in this study were pre-treated with metformin all that
can be concluded is that switchover did not lead to any
change. Likewise, no change was reported for vitamin
B12 levels following switchover indicating lack of any
specific effect of the metformin XR tablet on absorption
of this vitamin. Greater understanding of metformin and
its interaction with vitamin B12 levels has come from
recent studies [32].
Finally, limitations of our study include the open label
design with no comparator. However, much is known
about metformin having been used in clinical medicine
for over 50 years [10]. Of some concern was the large
number of patients who left the study, during follow-up
but the reasons were mostly social and economic ones
arising from repeated attendance at the clinic. Measures
of tolerability and patient satisfaction were recorded but
using simple questionning techniques rather than vali-
dated quality of life measures.
Conclusions
Switchover to metformin XR resulted in a significant
improvement in gastrointestinal tolerability with marked
reductions in diarrhoea and nausea. Improved patient
satisfaction and well being led to the XR once-a-day
tablet being preferred in a high majority of patients.
When considered alongside the comparative efficacy of
the metformin XR tablet versus standard metformin,
this new formulation of metformin has the potential to
improve compliance and long-term health outcomes.
This is the goal if the aim of therapy is to reduce excess
morbidity and mortality in patients with type 2 diabetes.
Key messages
￿ Optimising metformin therapy is hindered by mul-
tiple daily dosing and persistent gastrointestinal side
effects in some patients.
￿ Extended release metformin is associated with bet-
ter tolerability and is preferred by patients when
given the choice.
￿ Better compliance will lead to fewer long-term
complications and better health outcomes.
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